摘要:
The present invention is relevant to human medicine, and, in particular, to the use of Epidermal Growth Factor (EGF) in a pharmaceutical composition, said composition is administered through infiltration at the periphery of nerve trunks and/or ganglia, for the morphofunctional restoration of peripheral nerves in painful, sensitive-motor neuropathy, as well as ischemic neuritis. It is also relevant to an EGF containing composition, where this molecule can be formulated together with anesthetic or analgesic drugs, or encapsulated in microspheres, and their use for the morphofunctional restoration of peripheral nerves in painful, sensitive-motor neuropathy, as well as in ischemic neuritis.
摘要:
The current invention describes chimeric vaccine antigens against the virus that causes the Classic Swine Fever (CSFV). Such vaccine antigens are based on viral subunits coupled to proteins able to stimulate cellular and humoral immune system. Chimeric antigens can be produced in expression systems that guarantee a correct tertiary structure folding of the chimeric molecules, which constitute the essence of the current invention. The vaccine formulations containing such chimeric antigens induce an early and potent immune response on vaccinated pigs and confer full protection against CSFV. Moreover, the resultant vaccine formulations prevent the viral transmission from sows to their offspring. The chimeric antigens, as well as the resultant vaccine formulations, can be applied in animal health as vaccines for preventive use in swine.
摘要:
This invention describe the a pharmaceutical compound having the capsid protein of Dengue virus capable of induce in the receptor a protective immune response before the viral challenge without inducing the Abdependent enhancement phenomenon.
摘要:
Chemical compounds identified by in silico molecular modelling, and having an structure that allows the blocking of the phosphorylation event, through the interaction of such compounds with the phosphorylation domain or its milieu in the substrates of the Casein Kinase 2 enzyme. This invention comprises also the pharmaceutical compositions containing such compounds, and their use in the preparation of medicines for the treatment of diseases related with neoplasic processes.
摘要:
A method based on the selective isolation of peptides originated by the cleavage at the C-terminal end of the arginine residues and do not possess lysine inside their sequences (péptidos RRnK), is described. The method is based on the blocking of amino groups of the LEP peptides and the separation of the RRnK peptides and the modified peptides by using a chromatography column or a chemical reaction of the modified peptides with a solid support. The method simplifies the complex mixtures of peptides by isolating selectively an average of 4 peptides/protein and it guarantees a coverage of 88% of the proteomes, its specificity and selectivity are very high (>95%), it is compatible with different types of isotopic labeling ( 13 C, 18 O or 15 N) and it is useful for the determination of the differential expression of proteins without the necessity of using the two-dimensional electrophoresis.
摘要:
The invention is related with the chemical synthesis for increase the growth rate in marketable fish and custracean. The aim of this invention is supply GHRP-6 to induce directly or indirectly the release of growthing hormone or like, to produce the increase of circulating growthing hormone level in the blood of the fishes. The peptide is stable, soluble and biologically active. The peptide is able to stimulate growth, improve the larvae quality, and increase the defense against pathogen agents, the dry weight, the protein concentration and the RNA in muscle of fish and crustaceans.
摘要:
The present invention describes a method of selective peptide isolation for the identification and quantitative analysis of proteins in complex mixture. The method comprises the selective isolation from every protein of those peptides that neither contain arginine nor histidine (NHNR peptides), and the determination of the relative concentrations of one or several proteins in different samples from the ratio between the areas of the estimated theoretical spectra for the NHNR peptides labeled with different isotopes in each sample. The determination of the relative concentration of proteins is valid for any type of isotopic label of the NHNR peptides. The method avoids the separation and purification of the proteins present in a complex mixture, and the analysis of all peptides generated from the enzymatic digest of the samples. The method is applicable to the identification of proteins with vacunal, therapeutic and diagnostic aims.